Drug Profile

LYS FXS01

Alternative Names: Fragile X syndrome gene therapy - Lysogene; FXS01; LYS-FXS01

Latest Information Update: 22 Apr 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Conectus Alsace; Institute of Genetics and Molecular and Cellular Biology
Class Gene therapies; Neuroprotectants
Mechanism of Action Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

21 Apr 2022 Preclinical trials in Fragile X syndrome in France
21 Apr 2022 Preclinical trials in Fragile X syndrome in USA
21 Apr 2022 Pharmacodynamics data from a preclinical trial in Fragile X syndrome released by Lysogene

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com